» Articles » PMID: 22348503

Nanoparticle Tracking Analysis Monitors Microvesicle and Exosome Secretion from Immune Cells

Overview
Journal Immunology
Date 2012 Feb 22
PMID 22348503
Citations 147
Authors
Affiliations
Soon will be listed here.
Abstract

Nanoparticle tracking analysis permits the determination of both the size distribution and relative concentration of microvesicles, including exosomes, in the supernatants of cultured cells and biological fluids. We have studied the release of microvesicles from the human lymphoblastoid T-cell lines Jurkat and CEM. Unstimulated, both cell lines release microvesicles in the size range 70-90 nm, which can be depleted from the supernatant by ultracentrifugation at 100 000 g, and by anti-CD45 magnetic beads, and which by immunoblotting also contain the exosome-associated proteins Alix and Tsg101. Incubation with known potentiators of exosome release, the ionophores monensin and A23187, resulted in a significant increase in microvesicle release that was both time and concentration dependent. Mass spectrometric analysis of proteins isolated from ultracentrifuged supernatants of A23187-treated cells revealed the presence of exosome-associated proteins including heat-shock protein 90, tubulin, elongation factor α1, actin and glyceraldehyde 3-phosphate dehydrogenase. Additionally, treatment of peripheral blood monocyte-derived dendritic cells with bacterial lipopolysaccharide displayed an increase in secreted microvesicles. Consequently, nanoparticle tracking analysis can be effectively applied to monitor microvesicle release from cells of the immune system.

Citing Articles

Extracellular vesicle mimetics engineered from mesenchymal stem cells and curcumin promote fibrosis regression in a mouse model of thioacetamide-induced liver fibrosis.

Gopal A, Gangadaran P, Rajendran R, Oh J, Lee H, Hong C Regen Ther. 2024; 26:911-921.

PMID: 39502438 PMC: 11535984. DOI: 10.1016/j.reth.2024.10.005.


Exosome-based cell therapy for diabetic foot ulcers: Present and prospect.

Yang Z, Yang M, Rui S, Hao W, Wu X, Guo L Heliyon. 2024; 10(20):e39251.

PMID: 39498056 PMC: 11532254. DOI: 10.1016/j.heliyon.2024.e39251.


Nanoparticle Tracking Analysis: An Effective Tool to Characterize Extracellular Vesicles.

Kowkabany G, Bao Y Molecules. 2024; 29(19).

PMID: 39407601 PMC: 11477862. DOI: 10.3390/molecules29194672.


Exosome-mediated delivery of siRNA molecules in cancer therapy: triumphs and challenges.

Ubanako P, Mirza S, Ruff P, Penny C Front Mol Biosci. 2024; 11:1447953.

PMID: 39355533 PMC: 11442288. DOI: 10.3389/fmolb.2024.1447953.


Neuroinflammatory responses and blood-brain barrier injury in chronic alcohol exposure: role of purinergic P2 × 7 Receptor signaling.

Togre N, Mekala N, Bhoj P, Mogadala N, Winfield M, Trivedi J J Neuroinflammation. 2024; 21(1):244.

PMID: 39342243 PMC: 11439317. DOI: 10.1186/s12974-024-03230-4.


References
1.
Skog J, Wurdinger T, van Rijn S, Meijer D, Gainche L, Sena-Esteves M . Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10(12):1470-6. PMC: 3423894. DOI: 10.1038/ncb1800. View

2.
Savina A, Furlan M, Vidal M, Colombo M . Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J Biol Chem. 2003; 278(22):20083-90. DOI: 10.1074/jbc.M301642200. View

3.
Morse M, Garst J, Osada T, Khan S, Hobeika A, Clay T . A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med. 2005; 3(1):9. PMC: 551593. DOI: 10.1186/1479-5876-3-9. View

4.
Clayton A, Mitchell J, Court J, Linnane S, Mason M, Tabi Z . Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol. 2008; 180(11):7249-58. DOI: 10.4049/jimmunol.180.11.7249. View

5.
Webber J, Steadman R, Mason M, Tabi Z, Clayton A . Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res. 2010; 70(23):9621-30. DOI: 10.1158/0008-5472.CAN-10-1722. View